logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO-IO 2019 – New immunotherapy combination for neoadjuvant treatment of early colorectal cancer

Preliminary results from the NICHE study show ipilimumab+nivolumab for early colorectal carcinoma is safe and effective in the neoadjuvant setting.